

Monocyte Activation Test – MAT

Use and Implementation of MAT

Speakers from Authorities

DR KLAUS CUSSLER

Paul-Ehrlich-Institut, Germany

DR INGO SPREITZER

Paul-Ehrlich-Institut, Germany

DR DON SINGER

USP, USA

DR KARIN NORDGREN

NIBSC

Speakers from Industry and Science

KRISTIN KOWALICK

Labor L+S AG, Germany

DR ANJA FRITSCH

Conforma, France

**DR KATARZYNA MARCINI-
AK-DARMOCHWAL,**

*Charles River Laboratories,
Ireland*

DIPL ING MAIKE PIEHLER

Microcoat, Germany

DR ASTRID VISSER

Sanquin, The Netherlands

DR WALTER ZWISLER

Zwislser Laboratory, Germany




Image: PEI

7 September 2016, Frankfurt/Langen, Germany

Join us at the pre-workshop **Get-Together** on 6 September
in the Steigenberger Hotel Frankfurt-Langen

HIGHLIGHTS:

- Regulatory Background in Europe and US
- Status Report on the Development, Validation and Regulatory Acceptance of Alternative Methods and Approaches
- Use of Cell Lines
- Advantages and Pitfalls
- MAT - Batch release of modern vaccines

10th Anniversary of ECA's
Rapid Microbiological
Methods Group



This conference is recognised for the ECA GMP Certification Programme „Certified Microbiological Laboratory Manager“. Please find details at www.gmp-certification.eu

Monocyte Activation Test – MAT

06 and 07 September 2016, Frankfurt/Langen, Germany

Invitation

Dear Colleagues,



The first workshop on MAT was held at the Paul-Ehrlich-Institute on 22 November 1999, so to say in the last Millennium. This was my first visit to the PEI (still working on my PhD thesis in Constance), the icy weather caused many accidents and obstacles on the road.

Since then we have seen a lot of obstacles hindering the widespread implementation of the MAT, although during the last 17 years an enormous effort and progress was achieved by several esteemed partners within the community.

The European validations (together with ECCVAM) were finalized and accepted successfully. With continuous support by the German Pharmacopeia, the EDQM MAT Expert group was re-established and finally the MAT Monograph 2.6.30. was implemented into the European Pharmacopeia in 2010. Meanwhile, the EDQM performed an MAT survey to improve the MAT monograph. The BET Guideline 5.1.10. and the Rabbit Pyrogen Test (RPT) monograph 2.6.8. have been revised to clarify the prioritisation of the MAT compared to the RPT (especially in regard to the EU Directive 2010/63). Furthermore, the microbial safety unit at the PEI discontinued the RPT at the end of 2014, thus highlighting the significance of the MAT.

In a series of workshops and conferences MAT experts shared their thoughts with those who were interested and/or affected by these developments.

Finally, after more than 20 years, we have reached a point where we have to do what we worked for all the time: Replacing a good and predictive animal test with an even better alternative method.

The purpose of this workshop is to provide the participants with guidance and support for the upcoming changes, a vision which both the PEI and the ECA share. Experts from Authority, Industry and Contract Laboratories will provide insight into their experiences with the implementation of MAT.

With best regards,
Dr Ingo Spreitzer, PEI

Background

During recent years manifold advances have taken place to replace both, Rabbit Pyrogen Test (RPT) and in some cases the Limulus Amebocyte Lysate Test (LAL).

Some of the reasons are:

- Animal experiments have to be reduced. Especially with the current EU Regulations. Also the LAL test is not a true in vitro test.
- Get an alternative Test, where the classic LAL shows some gaps, e.g. contamination of biologicals by non-endotoxin pyrogens not detectable in LAL test is not unlikely.
- LAL reagent has to be harvested from Horseshoe Crabs. An environmental or an ecological disaster could extinguish the Limulus population.

True In-vitro Pyrogen Tests (IVPT) have been developed in several European countries (United Kingdom, The Netherlands, Switzerland, Germany) in national and international research projects. The tests imitate the central step of human fever reaction, i.e. the activation of human monocytes by endotoxin as well as non-endotoxin pyrogens. One result of all these activities is the Monocyte Activation Test (MAT).

This unique event is jointly organised by the Paul Ehrlich Institut – Federal Institute for Vaccines and Biomedicines and the ECA Academy to bring together European industry and regulatory representatives in order to discuss the practical experiences in using MAT, the advantages, the pitfalls, the available systems as well as the regulatory experiences.

Target Audience

This workshop is addressed to all persons of

- pharmaceutical manufacturers, biopharmaceutical companies, medical device manufacturers, contract laboratories, tissue establishments, and authorities
- who are involved in Endotoxin and Pyrogen testing in development, IPC or release.

Moderator/Chair

Dr Isabell Bekeredjian-Ding, PEI and member of the Microbiology Group Advisory Board and
Dr Sven Deutschmann, Roche Diagnostics, Chair ECA Pharmaceutical Microbiology Working Group

Programme

Current Developments on MAT

- Drivers for MAT-related pharmacopeial changes: Users and EU Directive
- The interaction of 5.1.10., 2.6.8. and 2.6.30.
- MAT availability
- PEI position on MAT

DR INGO SPREITZER, PEI

USP Requirements and Regulatory Thinking

- Current Regulatory Background
- Expected Developments

DR DON SINGER, USP

Implementation of Alternatives to Animal Safety

- History – the Issue of solving Salvarsan “Sodium Chloride/Water Fever”
- Development of JEG 3R (replacement, reduction, refinement)

DR KLAUS CUSSLER, PEI

MAT – Pitfalls and Lessons learned

- MAT - one test various test procedures
 - Pros & cons from the perspective of a contract laboratory
- Critical aspects of the test
 - Blood source
 - Realization of the Ph.Eur. requirements: 4 Replicates, LOD
- Summary: Points to consider for the routine use of MAT

KRISTIN KOWALICK, L+S AG

MAT using cryopreserved pooled PBMCs

- MAT as pyrogen test
- Characteristics and Performance of MAT assay of Sanquin
- Examples of validation and drug release testing of plasma derived products
- Critical aspects and tips for performing MAT

DR ASTRID VISSER, SANQUIN

MAT use for Medical Devices

- Medical Devices vs pharmaceutical samples
- Pooled human cryoblood experience

DR WALTER ZWISLER, ZWISLER LABORATORIUM

MAT Testing with Monomac6 Cell Line

- Advantages of performing the MAT in a routine Laboratory using a cell line
- Assay characteristics
- Experiences with validations and routine testing

DR ANJA FRITSCH, CONFARMA

Experiences with MAT

- Evaluation of a one-step MAT assay
- Feasibility data using various pyrogen
- Validation concept for MAT as a generic pyrogen test

MAIKE PIEHLER, MICROCOAT

MAT Batch Release of Modern Vaccines

- OMV-based vaccines and pyrogen testing
- MAT-approach for batch release

DR KARIN NORDGREN, NIBSC

Overcoming the Challenges in Establishing Routine MAT Assay

- The MAT assay and testing of different sample/product types
- A look at the types of interference that may be seen with the assay
- Controlling the robustness of the MAT assay

DR KATARZYNA MARCINIAK-DARMOCHWAL, CRL

Speakers

DR KLAUS CUSSLER,

Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines

Dr Cussler studied Veterinary Medicine at the University of Mainz. He is a specialist in Veterinary Microbiology and Animal Welfare. Since 1987 he is Head of Veterinary Pharmacovigilance at the Paul-Ehrlich Institut.

DR ANJA FRITSCH,

Chief Scientific Officer, Confarma France Sarl, Molecular Biology, France

Anja Fritsch gained her PhD in 2004. After a post-doc period at the University of Freiburg, she joined Confarma in 2011 as Chief Scientific Officer. Her main field of interest is the development of cell-based assay systems for the analysis of variety of biological reactions.

KRISTIN KOWALICK,

Labor L+S AG, Germany

Kristin is a biologist by training and is Head of the R&D laboratory at L+S AG. The responsibility of this lab is the evaluation, testing and validation of new customized microbiological methods.

DR KATARZYNA MARCINIAK-DARMOCHWAL,

Charles River Laboratories, Ireland

Katarzyna studied Biology at the University of Warmia and Mazury. After 4 years as academic teacher and research technician, she joined Lonza Biologics at Slough in 2007. From 2012 – 2015 she worked for UCB as Senior Method Development and Validation Scientist. 2015 she came to CRL as Senior Project Leader Method Development Department.

DR KARIN NORDGREN,

NIBSC, Medicines and Healthcare Products Regulatory Agency, UK

In her current position, Karin works at the Biotherapeutics Group of the National Institute for Biological Standards and Control.

DIPL ING MAIKE PIEHLER,

Microcoat Biotechnology GmbH, Germany

Maike studied Biotechnology in Hamburg. After different positions in product development at Hyglos and quality management at Microcoat, she is currently the head of the department "Service Endotoxin Detection" at Microcoat.

DR DONALD C. SINGER,

USP Microbiology Committee, Vice-Chair, USA

Donald C. Singer is a graduate of Boston University and University of Dayton. He is a member of the USP Microbiology Committee of Experts and is Global Lead Manager, Microbiology R&D for GlaxoSmithKline. He is a Certified Specialist Microbiologist in Consumer and Industrial Microbiology and has been a Malcolm Baldrige National Quality Award Examiner.

DR INGO SPREITZER,

Paul-Ehrlich-Institut, Germany Agency for Vaccines and Biomedicines, Germany

Ingo Spreitzer studied Biology at the University of Mainz, Germany, and was awarded a doctorate in 2000. Since 2001 he has been working as a scientist at the Paul-Ehrlich-Institut. In October 2004 he was appointed Deputy head of Section 1/3, "Microbial Safety and Parasitology". Duties: Pyrogen testing (rabbit and alternatives), LAL Testing.

ASTRID VISSER,

Sanquin Plasma Products, The Netherlands

Astrid studied Biology at the University of Amsterdam and held a PhD in Medicine. After a time as postdoc she joined Phillips for several years as clinical scientist and later as project leader. 2012 she started working for Sanquin. Her current position is Business Development Manager Sanquin Reagents, project leader MAT development.

DR WALTER ZWISLER,

CEO of Zwisler Laboratorium GmbH, Germany

Dr Walter Zwisler studied Biology at the University of Konstanz and got his PhD at the University of Oldenburg. Since 2003 he is deeply involved in the In vitro Pyrogen Testing with human cryo and fresh blood. With government-funded research projects and several thousand tested samples (medical devices and pharmaceutical samples) the Zwisler Lab is well versed with the MAT.

The Paul-Ehrlich-Institut is the Federal Institute for Vaccines and Biomedicines. It is a senior federal authority in the field of medicinal products providing services in public health.

The Paul-Ehrlich-Institut assesses and monitors the benefit - risk balance before, during and after the marketing authorisation of biomedicines for human use and immunological medicines for veterinary use.

The Paul-Ehrlich-Institut's own experimental research in the field of life sciences is an indispensable basis for the fulfilment its duties. The Paul-Ehrlich-Institut reports to the German Federal Ministry of Health (Bundesministerium für Gesundheit).

The ECA Foundation is the leading European organisation with regard to pharmaceutical Quality Assurance and GMP compliance.

The goals of the ECA Foundation are still the same as follows:

- to facilitate the exchange of information between representatives of the industry, the medicines authorities and the universities in the field of pharmaceutical quality assurance, especially with regard to the area of Good Manufacturing Practice (GMP)
- to promote the move towards a harmonised set of GMP and regulatory guidelines, by providing information and interpretation of new or updated guidances,
- and to issue position papers where appropriate to influence and harmonise regulations and to facilitate networking.

The Foundation is comprised of an educational organisation (ECA Academy) and various non-profit interest and working groups. The modern structure of the ECA Foundation allows to develop and include the activities of these groups and to have more flexibility to build new groups that support the needs of our ECA Academy's members. Close to 4,000 members in the Foundation's educational organisation ECA Academy from all over Europe and abroad represent more than 60 countries.

Special offer with Lufthansa - up to 20% discounted travel for all ECA Events Attendees

As an ECA course or conference attendee, you will receive up to 20% discounted travel fares (according to availability). And as Lufthansa German Airlines offers a comprehensive global route network linking major cities around the world you will most likely be able to benefit from these special prices and conditions.

And this is how it works: Once you registered for a course or conference you will receive a link together with your registration confirmation. Opening that link will take you to the Mobility Partner Program website where you can enter a code in the "Access to Event Booking" area you will also receive. This will take you into an online booking platform* that will automatically calculate the discount offered or provide you with an even better offer if another promotional fare is available.

We look forward to welcoming at one of our next events – and we already wish you a pleasant flight!

*Please note: You may have to enable pop-ups on the Mobility Partner Program website – other-wise the booking platform window will not open.

Easy Registration



Reservation Form:
CONCEPT HEIDELBERG
P.O. Box 10 17 64
69007 Heidelberg, Germany



Reservation Form:
+49 6221 84 44 34



e-mail:
info@concept-heidelberg.de



Internet:
www.gmp-compliance.org

Date

Get-Together in the Steigenberger Hotel
Frankfurt-Langen on
Tuesday, 06 September 2016,
18.30 h – approx. 21.30 h

Workshop at PEI on
Wednesday, 07 September, 09.30 – 16.30 h
(Registration and coffee 09.00 – 09.30 h)

Venues

Get-Together and overnight stays:

Steigenberger Hotel Frankfurt-Langen
Robert-Bosch-Str. 26
63225 Langen/Frankfurt, Germany
Phone +49 (0)6103 972 0
Fax +49 (0)6103 972 555

For hotel guests, the Steigenberger Hotel
offers a free of charge shuttle service from
Frankfurt Airport to the hotel (approx.
16 km distance)

Workshop:

Paul-Ehrlich-Institut
German Federal Institut for Vaccines and
Biomedicines
Paul-Ehrlich-Straße 51-59
63225 Langen, Germany
Phone +49 (0)6103 770

Fees (per delegate plus VAT)

ECA Members € 690
APIC Members € 740
Non-ECA Members € 790
EU GMP Inspectorates € 395
Academics (Students, Post docs etc.) € 395
The conference fee is payable in advance
after receipt of invoice and includes con-
ference documentation, Get-Together on
the evening before the workshop, and
on 7 September lunch and all refreshments.
VAT is reclaimable.

Conference Language

The official conference language will be
English.

Accommodation

CONCEPT HEIDELBERG has reserved a
limited number of rooms in the conference
hotel. You will receive a room reservation
form when you have registered for the
conference. Reservation should be made
directly with the hotel. Early reservation is
recommended.

Organisation and Contact

ECA has entrusted Concept Heidelberg
with the organisation of this event.

CONCEPT HEIDELBERG
P.O. Box 10 17 64
69007 Heidelberg, GERMANY
Phone +49 (0) 62 21/84 44-0
Fax +49 (0) 62 21/84 44 34
E-mail: info@concept-heidelberg.de
www.concept-heidelberg.de

For questions regarding content:

Mr Axel Schroeder (Operations Director) at
+49-62 21/84 44 10 or per e-mail at
schroeder@concept-heidelberg.de.

For questions regarding reservation, hotel, organisation etc.:

Ms Nicole Bach (Organisation Manager) at
+49-62 21/84 44 22 or per e-mail at
bach@concept-heidelberg.de.

Langen is excellently connected to the road and rail network

Coming by car, you can reach Langen via the motorway A5, exit Langen/Mörfelden and the A661, exit Langen. S-Bahn (suburban railway) and local trains depart regularly from the main stations in Frankfurt and Darmstadt. Just a few kilometres away from Langen is Frankfurt international airport, one of the major air traffic hubs in Europe, as well as the Egelsbach airfield, Germany's most important airfield of general aviation.

If the bill-to-address deviates from the specification
to the right, please fill out here:

Reservation Form (Please complete in full)

+49 6221 84 44 34

Monocyte Activation Test – MAT

7 September 2016, Frankfurt/Langen, Germany

☐ Yes, I will also take part in the **Get-Together on 6 September 2016** at the Steigenberger
Hotel Frankfurt-Langen

☐ Mr ☐ Ms

Title, first name, surname

Company

Department

Important: Please indicate your company's VAT ID Number

Please indicate the Purchase Order Number, if applicable

Street / P.O. Box

City

Zip Code

Country

Phone / Fax

E-Mail (Please fill in)

General terms and conditions

If you cannot attend the confer-
ence you have two options:

1. We are happy to welcome a sub-
stitute colleague at any time.
2. If you have to cancel entirely we must charge
the following processing fees: Cancellation
■ until 2 weeks prior to the conference 10 %,
■ until 1 weeks prior to the conference 50 %
■ within 1 week prior to the conference 100 %.
CONCEPT HEIDELBERG reserves the right to
change the materials, instructors, or speakers

without notice or to cancel an event.

If the event must be cancelled, registrants will be
notified as soon as possible and will receive a full
refund of fees paid. CONCEPT HEIDELBERG will
not be responsible for discount airfare penalties
or other costs incurred due to a cancellation.

Terms of payment: Payable without deduc-
tions within 10 days after receipt of invoice.

Important: This is a binding registration and
above fees are due in case of cancella-
tion or non-appearance. If you cannot take
part, you have to inform us in writing.

The cancellation fee will then be calcu-
lated according to the point of time at
which we receive your message.

In case you do not appear at the event without
having informed us, you will have to pay the
full registration fee, even if you have not made
the payment yet. Only after we have received
your payment, you are entitled to participate
in the conference (receipt of payment will
not be confirmed)! (As of January 2012).

Privacy Policy: By registering for this event,
I accept the processing of my Personal Data.
Concept Heidelberg will use my data for the
processing of this order, for which I hereby de-
clare to agree that my personal data is stored and
processed. Concept Heidelberg will only send
me information in relation with this order or simi-
lar ones. My personal data will not be disclosed
to third parties (see also the privacy policy at
http://www.gmp-compliance.org/eca_privacy.
html). I note that I can ask for the modification,
correction or deletion of my data at any time via
the contact form on this website.